论文部分内容阅读
目的评价紫杉醇联合奈达铂治疗晚期非小细胞肺癌的疗效和毒副反应。方法 33例经病理确诊的晚期非小细胞肺癌患者,初治或复治,ⅢB期(伴胸腔积液)或Ⅳ期,重要脏器功能正常,PS评分0～2分的患者入组。紫杉醇175mg/m2,第1天,奈达铂80mg/m2,第1天,每21d为一疗程。结果本组33例患者均已完成至少2个疗程化疗。初治组和复治组的有效率分别为41.1%、31.3%,中位生存期分别为425d和343d。发生白细胞减少和血小板减少的疗程数分别占总疗程数的65.5%和19%,无治疗相关性死亡。结论紫杉醇联合奈达铂治疗晚期非小细胞肺癌,疗效确切,对顺铂耐药患者仍然有效,耐受性好。
Objective To evaluate the efficacy and side effects of paclitaxel combined with nedaplatin in the treatment of advanced non-small cell lung cancer. Methods Thirty-three patients with advanced non-small cell lung cancer diagnosed by pathology were enrolled in the study. The patients with initial or re-treatment, stage ⅢB (with pleural effusion) or stage Ⅳ, vital organs with normal function and with PS score of 0 to 2 were enrolled. Paclitaxel 175mg / m2, the first day, nedaplatin 80mg / m2, the first day, every 21d for a course of treatment. Results The group of 33 patients have completed at least 2 courses of chemotherapy. The effective rates of the initial treatment group and the retreatment group were 41.1% and 31.3%, respectively, and the median survival time was 425 days and 343 days respectively. The number of courses of leukopenia and thrombocytopenia accounted for 65.5% and 19% of the total number of courses, respectively, with no treatment-related deaths. Conclusion paclitaxel combined with nedaplatin in the treatment of advanced non-small cell lung cancer, curative effect is exact, cisplatin-resistant patients are still effective, well tolerated.